Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,949.00    -78.00 (-2.58%)
Bid:
2,942.00
Ask:
2,946.00
Spread: 4.00 (0.136%)
Market Cap: £4.11b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Interim Management Statement

25 Apr 2013 07:00

RNS Number : 1773D
Croda International PLC
25 April 2013
 



25 April 2013

 

Croda International Plc

 

AGM and Interim Management Statement

 

SOLID START TO 2013; OUTLOOK MAINTAINED

 

Croda International Plc today announces its Interim Management Statement for the period since 31 December 2012.

 

Pre-tax profits for the first quarter of 2013 were up 6.5% to £65.1m (2012: £61.1m). This was achieved against a particularly strong performance in the same period in 2012 and despite the adverse impact of an earlier Easter this year.

 

Group turnover grew marginally by 0.4% to £283.1m (2012: £281.9m). Consumer Care sales were broadly stable at £158.4m (2012: £159.1m), with Crop Care weaker due to the poor weather experienced in a number of regions throughout the period. Personal Care and Health Care sales were flat. Performance Technologies sales were also stable, down only 0.3% to £102.4m (2012: £102.7m) with continuing weakness in Lubricants being the major factor. Industrial Chemicals sales were up 10.4% at £22.3m (2012: £20.2m).

 

Group operating profits were up 4.0% to £68.0m (2012: £65.4m) increasing return on sales by a further 0.8 percentage points to 24.0% for the quarter. Profits and margins improved in all three of our reporting segments. Consumer Care profits increased 2.3% to £49.2m (2012: £48.1m) with return on sales up at 31.1% (2012: 30.2%). Performance Technologies profits increased 1.9% to £16.1m (2012: £15.8m) with return on sales up at 15.7% (2012: 15.4%). In Industrial Chemicals, profit increased to £2.7m (2012: £1.5m) as a result of the strong sales uplift and favourable commodity prices.

 

Interest costs decreased due to the reduced pension fund deficit, helping achieve the 6.5% increase in pre-tax profits referred to earlier.

 

There has been no significant change in Croda's financial position during the period. Underlying cash generation in the quarter continued to be good and at the end of March 2013 net debt was £211.1m, an increase of only £3.4m versus the year end despite a payment of £38m into the UK pension fund in January.

 

The Board believes that the Q1 result represents a solid start to the year. The outlook provided in February is unchanged and we expect to report further progress in 2013.

 

 

For further information, please contact:

 

Steve Foots, Group Chief Executive

Tel: 01405 860551

Sean Christie, Group Finance Director

Charlie Armitstead/ Rosie Oddy

Pendomer Communications

Tel: 020 3603 5220

 

The company will host a conference call for analysts at 8.00am (BST) today:

Dial-In: +44 203 426 2845

Please quote "Croda International"to gain access to the call

 

Croda International Plc

Unaudited income statement before tax and exceptional items

31 March 2013

 

3 months to

3 months to

31 March

31 March

2013

2012

Change

Consumer Care

158.4

159.1

-0.4%

Performance Technologies

102.4

102.7

-0.3%

Industrial Chemicals

22.3

20.1

+10.9%

Revenues from continuing operations

283.1

281.9

+0.4%

Consumer Care

49.2

48.1

+2.3%

Performance Technologies

16.1

15.8

+1.9%

Industrial Chemicals

2.7

1.5

+80.0%

Operating profit from continuing operations

68.0

65.4

+4.0%

Net bank and loan interest payable

(1.7)

(2.0)

Net retirement benefit scheme financing

(1.2)

(2.3)

Profit before tax from continuing operations

65.1

61.1

+6.5%

Operating margin

24.0%

23.2%

 

Analysis of turnover uplift for continuing operations

Volume

+0.1%

Mix and price

-0.9%

Underlying

-0.8%

Acquisitions

+0.1%

Currency translation

+1.1%

+0.4%

This statement has been prepared in accordance with the revised IAS19 rules regarding the accounting for post-retirement benefits. 2012 results have been restated so the figures are comparable.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSKMGZDGDLGFZZ
Date   Source Headline
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding
4th Aug 20253:21 pmRNSDirector/PDMR Shareholding
4th Aug 202511:03 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.